Societal challenges of precision medicine: Bringing order to chaos

the IBCD-Faculty

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

The increasing number of drugs targeting specific proteins implicated in tumourigenesis and the commercial promotion of relatively affordable genome-wide analyses has led to an increasing expectation among patients with cancer that they can now receive effective personalised treatment based on the often complex genomic signature of their tumour. For such approaches to work in routine practice, the development of correspondingly complex biomarker assays through an appropriate and rigorous regulatory framework will be required. It is becoming increasingly evident that a re-engineering of clinical research is necessary so that regulatory considerations and procedures facilitate the efficient translation of these required biomarker assays from the discovery setting through to clinical application. This article discusses the practical requirements and challenges of developing such new precision medicine strategies, based on leveraging complex genomic profiles, as discussed at the Innovation and Biomarkers in Cancer Drug Development meeting (8th–9th September 2016, Brussels, Belgium).

Original languageEnglish (US)
Pages (from-to)325-334
Number of pages10
JournalEuropean Journal of Cancer
Volume84
DOIs
StatePublished - Oct 1 2017

Fingerprint

Precision Medicine
Biomarkers
Biomedical Engineering
Belgium
Drug Delivery Systems
Tumor Biomarkers
Neoplasms
Genome
Research
Pharmaceutical Preparations
Proteins
Therapeutics

Keywords

  • Assay validation
  • Biomarkers
  • Drug development
  • Preanalytical and analytical validation
  • Precision oncology
  • Regulatory sciences

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Societal challenges of precision medicine : Bringing order to chaos. / the IBCD-Faculty.

In: European Journal of Cancer, Vol. 84, 01.10.2017, p. 325-334.

Research output: Contribution to journalArticle

@article{d1a3364ad8bf456ab5a75f4f49061bbc,
title = "Societal challenges of precision medicine: Bringing order to chaos",
abstract = "The increasing number of drugs targeting specific proteins implicated in tumourigenesis and the commercial promotion of relatively affordable genome-wide analyses has led to an increasing expectation among patients with cancer that they can now receive effective personalised treatment based on the often complex genomic signature of their tumour. For such approaches to work in routine practice, the development of correspondingly complex biomarker assays through an appropriate and rigorous regulatory framework will be required. It is becoming increasingly evident that a re-engineering of clinical research is necessary so that regulatory considerations and procedures facilitate the efficient translation of these required biomarker assays from the discovery setting through to clinical application. This article discusses the practical requirements and challenges of developing such new precision medicine strategies, based on leveraging complex genomic profiles, as discussed at the Innovation and Biomarkers in Cancer Drug Development meeting (8th–9th September 2016, Brussels, Belgium).",
keywords = "Assay validation, Biomarkers, Drug development, Preanalytical and analytical validation, Precision oncology, Regulatory sciences",
author = "{the IBCD-Faculty} and Roberto Salgado and Helen Moore and Martens, {John W.M.} and Tracy Lively and Shakun Malik and Ultan McDermott and Stefan Michiels and Moscow, {Jeffrey A.} and Sabine Tejpar and Tawnya McKee and Denis Lacombe and Robert Becker and Philip Beer and Jonas Bergh and Jan Bogaerts and Simon Dovedi and Fojo, {Antonio T.} and Moritz Gerstung and Vassilis Golfinopoulos and Stephen Hewitt and Daniel Hochhauser and Hartmut Juhl and Robert Kinders and Thomas Lillie and Herbert, {Kim Lyerly} and Shyamala Maheswaran and Mehdi Mesri and Sumimasa Nagai and Irene Norstedt and Daniel O'Connor and Kathy Oliver and Oyen, {Wim J.G.} and Francesco Pignatti and Eric Polley and Nitzan Rosenfeld and Jan Schellens and Richard Schilsky and Erasmus Schneider and Adrian Senderowicz and Olli Tenhunen and {van Dongen}, Augustinus and Christine Vietz and Nils Wilking",
year = "2017",
month = "10",
day = "1",
doi = "10.1016/j.ejca.2017.07.028",
language = "English (US)",
volume = "84",
pages = "325--334",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Societal challenges of precision medicine

T2 - Bringing order to chaos

AU - the IBCD-Faculty

AU - Salgado, Roberto

AU - Moore, Helen

AU - Martens, John W.M.

AU - Lively, Tracy

AU - Malik, Shakun

AU - McDermott, Ultan

AU - Michiels, Stefan

AU - Moscow, Jeffrey A.

AU - Tejpar, Sabine

AU - McKee, Tawnya

AU - Lacombe, Denis

AU - Becker, Robert

AU - Beer, Philip

AU - Bergh, Jonas

AU - Bogaerts, Jan

AU - Dovedi, Simon

AU - Fojo, Antonio T.

AU - Gerstung, Moritz

AU - Golfinopoulos, Vassilis

AU - Hewitt, Stephen

AU - Hochhauser, Daniel

AU - Juhl, Hartmut

AU - Kinders, Robert

AU - Lillie, Thomas

AU - Herbert, Kim Lyerly

AU - Maheswaran, Shyamala

AU - Mesri, Mehdi

AU - Nagai, Sumimasa

AU - Norstedt, Irene

AU - O'Connor, Daniel

AU - Oliver, Kathy

AU - Oyen, Wim J.G.

AU - Pignatti, Francesco

AU - Polley, Eric

AU - Rosenfeld, Nitzan

AU - Schellens, Jan

AU - Schilsky, Richard

AU - Schneider, Erasmus

AU - Senderowicz, Adrian

AU - Tenhunen, Olli

AU - van Dongen, Augustinus

AU - Vietz, Christine

AU - Wilking, Nils

PY - 2017/10/1

Y1 - 2017/10/1

N2 - The increasing number of drugs targeting specific proteins implicated in tumourigenesis and the commercial promotion of relatively affordable genome-wide analyses has led to an increasing expectation among patients with cancer that they can now receive effective personalised treatment based on the often complex genomic signature of their tumour. For such approaches to work in routine practice, the development of correspondingly complex biomarker assays through an appropriate and rigorous regulatory framework will be required. It is becoming increasingly evident that a re-engineering of clinical research is necessary so that regulatory considerations and procedures facilitate the efficient translation of these required biomarker assays from the discovery setting through to clinical application. This article discusses the practical requirements and challenges of developing such new precision medicine strategies, based on leveraging complex genomic profiles, as discussed at the Innovation and Biomarkers in Cancer Drug Development meeting (8th–9th September 2016, Brussels, Belgium).

AB - The increasing number of drugs targeting specific proteins implicated in tumourigenesis and the commercial promotion of relatively affordable genome-wide analyses has led to an increasing expectation among patients with cancer that they can now receive effective personalised treatment based on the often complex genomic signature of their tumour. For such approaches to work in routine practice, the development of correspondingly complex biomarker assays through an appropriate and rigorous regulatory framework will be required. It is becoming increasingly evident that a re-engineering of clinical research is necessary so that regulatory considerations and procedures facilitate the efficient translation of these required biomarker assays from the discovery setting through to clinical application. This article discusses the practical requirements and challenges of developing such new precision medicine strategies, based on leveraging complex genomic profiles, as discussed at the Innovation and Biomarkers in Cancer Drug Development meeting (8th–9th September 2016, Brussels, Belgium).

KW - Assay validation

KW - Biomarkers

KW - Drug development

KW - Preanalytical and analytical validation

KW - Precision oncology

KW - Regulatory sciences

UR - http://www.scopus.com/inward/record.url?scp=85028944052&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028944052&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2017.07.028

DO - 10.1016/j.ejca.2017.07.028

M3 - Article

C2 - 28865260

AN - SCOPUS:85028944052

VL - 84

SP - 325

EP - 334

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

ER -